ABID MAHMOOD SALEEMI

• Develop and execute commercial strategies, programs, and initiatives across various therapeutic areas to drive revenue growth and increase market share
• Collaborate with cross-functional teams, including sales, marketing, medical affairs, and market access, to ensure alignment with business objectives and customer needs
• Cultivate and maintain strong relationships with key opinion leaders, external stakeholders, and industry associations to stay abreast of industry trends and insights
• Establish and manage key performance indicators (KPIs) to assess the effectiveness of commercial strategies and programs, making necessary adjustments for optimization.

• Led the development and implementation of commercial strategies, programs, and initiatives across multiple therapeutic areas to drive revenue growth, increase market share, and enhance customer experience
• Collaborated with cross-functional teams, including sales, marketing, medical affairs, and market access, to develop and execute integrated plans aligned with business objectives and customer needs
• Established and maintained strong relationships with key opinion leaders, external stakeholders, and industry associations to stay updated on the latest trends and insights in the pharmaceutical industry
• Developed and managed key performance indicators (KPIs) to monitor and measure the effectiveness of commercial strategies and programs, adjusting as needed to optimize results
• Major Achievements:
• Successfully implemented sales force effectiveness and marketing excellence strategies in 7 major markets, resulting in a monthly business growth of 10%
• Instituted a monthly sales review process using Power BI to analyze market dynamics, including sales and marketing activities, and identify gaps in customer, area, and brand performance
• Customized strategies were then devised to improve productivity and profitability of country operations in these 7 major markets
• Responsible for the commercial operations of Philippines (GOLY - 16%), Kenya (GOLY – 7%), Cambodia (GOLY – 9%), Uzbekistan (GOLY -234%), Sri Lanka (GOLY - 19%), Kazakhstan (GOLY - 24%) & Azerbaijan (Launched in 2023)

• Led the development and implementation of market entry strategies in alignment with ASPIN Pharma's commercial strategy
• Contributed to and was accountable for the Business Unit's input into the strategic planning process, delivering annual and 5-year business plans
• Held overall accountability and responsibility for marketing and sales plans, as well as annual financial and sales budgets
• Led and managed the implementation of approved activities in the business plan
• Regularly monitored performance indicators such as Market Plan Delivery, Sales Force activities, Sales Results, Budgeting, and Forecasting, taking appropriate actions when deviations from the plan were evident
• Ensured appropriate leadership and development of the team, including defining clear objectives, allocating resources, monitoring activities, providing fair rewards, and offering developmental opportunities
• Major Achievements:
• Successfully developed the team and achieved sales of PKR 4.17 Billion as per IMS MAT MAY-22, compared to PKR 3.64 Billion as per IMS MAT JUL-21
• Achieved value growth of 15.72% as per IMS MAT MAY-22, compared to -3.98% as per IMS MAT JUL-21
• Achieved unit growth of 12.44% as per IMS MAT MAY-22, compared to -9.51% as per IMS MAT JUL-21.

Led development and implementation of market entry strategies for Biotech and Cardiometabolic Divisions in alignment with SAMI Pharmaceuticals' commercial strategy

• Contributed to and was accountable for Business Unit's input into strategic planning process, delivering annual and 3-year business plans
• Major Achievements:
• Led and developed Biotech and Cardiometabolic teams, securing sales of PKR 629.5 million and PKR 683.8 million in 2020, respectively
• Successfully launched three products: Telarb Plus (Telmisartan + Amlodipine), Empoli (Empagliflozin), and Truva (Atorvastatin)
• Achieved sales milestones with theBiotech team: PKR 590 million in 2019, PKR 488 million in 2018, PKR 410 million in 2017, and PKR 312 million in 2016
• Developed a winning Biotech team and launched six products within three years
• OCVIR-V (Sofosbuvir + Velpatasvir) achieved number 1 position for 12-month value among 512 newly launched products in Pakistan (Industry Report Qtr2 2018).

• Created and implemented effective sales strategies, leading nationwide direct sales personnel to achieve corporate sales objectives
• Provided leadership through vision communication, active coaching, and development, while monitoring sales results against goals and taking corrective action when necessary
• Managed sales management, budget control, and incentive planning
• Ensured effective hiring, orientation, training, development, and retention of sales staff
• Provided supervision through field visits, observations, and measurement of results, including performance appraisals and salary reviews
• Established effective relationships and collaborations with other departments (Marketing, Finance, Customer Service, etc.) to address key business issues and opportunities
• Major Achievements:
• Achieved sales milestones for PegIntron: 327 Million in first half of 2015, 640 Million in 2014, and 509 Million in 2013, setting new landmarks for OBS
• Led 2 national teams (Hepatology & General Specialty).

• Managed, motivated, and developed team members to deliver business objectives and sales targets
• Ensured all team members had personal development plans to optimize performance and achieve all business KPIs
• Monitored and managed performance, contributing to key initiatives to drive and continually improve business performance, taking timely action when required
• Prioritized, planned, and organized workload effectively, delegating where appropriate to meet agreed deadlines
• Managed resources to maximize effectiveness of sales operations
• Major Achievements:
• Achieved sales milestone for PegIntron: 203 Million in 2012.